MedTrace Logo

Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy

NCT03493789 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2023-10-18

No results posted yet for this study

Summary

This trial studies how well fludeoxyglucose F-18 - positron emission tomography (PET) works in planning radiation therapy in participants with early non-small cell lung cancer, early stage lung cancer, or cancer that has spread to lungs from other parts of the body. Using PET in addition to the standard computed tomography to plan radiation therapy for cancer may help doctors to maximize the dose to the cancer and minimize the dose to normal tissues.

Conditions

  • Stage I Lung Cancer
  • Stage I Non-Small Cell Lung Cancer AJCC v7
  • Stage IA Non-Small Cell Lung Carcinoma AJCC v7
  • Stage IB Non-Small Cell Lung Carcinoma AJCC v7
  • Stage II Lung Cancer
  • Stage II Non-Small Cell Lung Cancer AJCC v7
  • Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
  • Stage IIB Non-Small Cell Lung Carcinoma AJCC v7

Interventions

DRUG

Fludeoxyglucose F-18

Given IV

PROCEDURE

Positron Emission Tomography (PET)

Undergo FDG-PET

RADIATION

Stereotactic Body Radiation Therapy (SBRT)

Undergo SBRT

Sponsors & Collaborators

  • RefleXion Medical

    collaborator INDUSTRY

  • National Cancer Institute (NCI)

    collaborator NIH

  • National Institutes of Health (NIH)

    collaborator NIH

  • Emory University

    lead OTHER

Principal Investigators

  • Kristin Higgins, MD · Emory University Hospital/Winship Cancer Institute

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-13
Primary Completion
2019-03-19
Completion
2019-03-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03493789 on ClinicalTrials.gov